Effective Respiratory Syncytial Virus vaccines in older adults-the long wait is over.

Respirology

School of Medicine, University of Western Australia, Perth, Western Australia, Australia.

Published: October 2024

Download full-text PDF

Source
http://dx.doi.org/10.1111/resp.14813DOI Listing

Publication Analysis

Top Keywords

effective respiratory
4
respiratory syncytial
4
syncytial virus
4
virus vaccines
4
vaccines older
4
older adults-the
4
adults-the long
4
long wait
4
effective
1
syncytial
1

Similar Publications

Intelligent Analgesia Management System in Postoperative Pain Management: A Retrospective Analysis.

J Perianesth Nurs

January 2025

Department of Nursing, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, China.

Purpose: This study aimed to explore the effect of an intelligent analgesia management system on postoperative pain management and the working mode of acute pain service.

Design: This is a retrospective cohort study.

Methods: A total of 584 patients who underwent laparoscopic abdominal surgery under general anesthesia and voluntarily received intravenous patient-controlled analgesia (PCA) between January 2018 and April 2020 at our hospital were selected.

View Article and Find Full Text PDF

Background: Understanding the interference patterns of respiratory viruses could be important for shedding light on potential strategies to combat these human infectious agents.

Objective: To investigate the possible interactions between adenovirus type 2 (AdV2), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and influenza A/H1N1 pandemic (H1N1pdm09) using the A549 cell line.

Methods: Single infections, co-infections, and superinfections (at 3 and 24 h after the first virus infection) were performed by varying the multiplicity of infection (MOI).

View Article and Find Full Text PDF

The ongoing global health crisis caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) necessitates the continuous development of innovative vaccine strategies, especially in light of emerging viral variants that could undermine the effectiveness of existing vaccines. In this study, we developed a recombinant virus-like particle (VLP) vaccine based on the Newcastle Disease Virus (NDV) platform, displaying a stabilized prefusion form of the SARS-CoV-2 spike (S) protein. This engineered S protein includes two proline substitutions (K986P, V987P) and a mutation at the cleavage site (RRAR to QQAQ), aimed at enhancing both its stability and immunogenicity.

View Article and Find Full Text PDF

Nasal spray treatments that inhibit the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) entry into nose and nasopharynx at early stages can be an appropriate approach to stop or delay the progression of the disease. We performed a prospective, randomized, double-blind, placebo-controlled, parallel-group, multicentric, phase II clinical trial comparing the rate of hospitalization due to COVID-19 infection between azelastine 0.1% nasal spray and placebo nasal spray treatment groups.

View Article and Find Full Text PDF

Bovine viral diarrhea virus (BVDV), a pestivirus in the family , is a major livestock pathogen. Horizontal transmission leads to acute transient infections via the oronasal route, whereas vertical transmission might lead to the birth of immunotolerant, persistently infected animals. In both cases, BVDV exerts an immunosuppressive effect, predisposing infected animals to secondary infections.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!